Oral mucositis in children with acute lymphoblastic leukemia after high- dose methotrexate treatment without delayed elimination of methotrexate: Relation to pharmacokinetic parameters of methotrexate

Pediatric Hematology and Oncology

Volumn 13, Issue 4, 1996, Pages 359-367

  Rask, Charlotte ^a,c   Albertioni, Freidoun ^b   Schrøder, Henrik ^a   Peterson, Curt ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NONE   (Denmark)

Author keywords

7 hydroxymethotrexate; methotrexate; oral mucositis; pharmacokinetics

Indexed keywords

METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; HIGH RISK POPULATION; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; MOUTH MUCOSA; MUCOSA INFLAMMATION;

EID: 0030056378     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019609030842     Document Type: Article

References (21)

1. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987;5: 2017-2031.
2. Diehl V, Kotz R, Salzer M, Winkler K, Baumgärtner G, Sekera J, Ramach W, Illinger J, Janka GE, Pralle H, Mcvie JG, Willoughby MLN, Engelhardt P, Oellerich M. Report on various clinical studies on high dose methotrexate in Europe (NON-EORTC). Onkologie. 1986;4:308-319.
3. Toth BB, Martin JW, Fleming TJ. Oral complications associated with cancer therapy. An M. D. Anderson Cancer Center experience. J Clin Periodontol. 1990;17:508-515.
4. Bergmann OJ. Oral infections and septicemia in immunocompromised patients with hematologic malignancies. J Clin Microbiol. 1988;26:2105-2109.
5. Ishii E, Yamada S, Higuchi S, Honjo T, Igarashi H, Kanemitsu S, Kai T, Ueda K. Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia. Med Pediatr Oncol 1989;17:429-432.
6. Oliff A, Bleyer WA, Poplack DG. Methotrexate-induced oral mucositis and salivary methotrexate concentrations. Cancer Chemother Pharmacol. 1979;2:225-226.
7. 2 to children with acute lymphoblastic leukemia. Med Pediatr Oncol 1990;18:217-224.
8. Erttmann R, Bielack S, Landbeck G. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy. Cancer Chemother Pharmacol. 1985;15:101-104.
9. Wolfrom C, Hepp R, Hartmann R, Breithaupt H, Henze G. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue. Eur J Clin Pharmacol. 1990;39:377-383.
10. Frickel C, Wolfrom C, Belz S, Fengler R, Henze G. Pharmacokinetics of MTX, 7-OHMTX and rescue folates in HDMTX treatment with low leucovorin rescue. Med Pediatr Oncol. 1993;21:568 (abstract no. P55).
11. Albertioni F, Rask C, Eksborg S, Hjelm Poulsen J, Beck O, Schrøder H, Peterson C. Evaluation of clinical assays for high-dose methotrexate measurements in plasma Clin Chem. 1996;42:1:39-44.
12. Kamen BA, Takach PL, Vatev R, Caston JD. A rapid radiochemical-ligand binding assay for methotrexate Anal Biochem. 1976;70:54-63.
13. Sheiner LB, Beal SL. Pharrnacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm. 1985;13:185-201.
14. Schrøder H, Jensen KB, Brandsborg M. Excretion of methotrexate in saliva and sweat. An occupational hygienic assessment. J Danish Med Assoc. 1988,150:2026-2029.
15. Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest. 1973;52:1804-1811.
16. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol. 1979;3: 161-166.
17. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297:630-634
18. Fabre G, Matherly LH, Fabre I, Cano JP, Goldman ID. Interactions between 7-hydroxymethotrexate and methotrexate at the cellular level in the Ehrlich ascites tumor in vitro. Cancer Res. 1984;44:970-975.
19. Gaukroger JM, Wilson L. Protection of cells from methotrexate toxicity by 7-hydroxymethotrexate. Br J Cancer. 1984;50:327-333.
20. Lankelma J, van-der-Klein E, Ramaekers F. The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett. 1980;9:133-142.
21. Sonis ST, Lindquist L, Van-Vugt A, Stewart AA, Stam K, Qu GY. Iwata KK, Haley JD. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Cancer Res. 1994;54:1135-1138.